
Nan Fung Group is a privately-held conglomerate founded in 1954 and headquartered in Hong Kong, with businesses spanning property development, financial investments, shipping, and life sciences. Its financial investment arm, NF Trinity (HK) Limited, manages investments across multiple asset classes including public securities, private direct investments, and private fund of funds, while Nan Fung Life Sciences has a $1.5 billion capital commitment to invest in life sciences companies.
30% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (40% of deals). Average disclosed round size is $95.1M (across 10 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
Meng Gao
Managing Director
Kenny Chan
Partner - Head of Public Investment
Arthur LIU
Director @ Nan Fung Trinity
Helen Zhu
Member of the Finance & Investment Committee
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| VVSPN | Series B | $60M | Oct 2020 |
| Series B | $100M | Oct 2020 | |
| Series C | $60M | Jan 2020 | |
| Series B | $66M | May 2018 | |
| Unknown | $40M | Jun 2016 | |
| Series C | $50M | May 2016 | |
| Series B | $40M | Jan 2016 | |
| Seed | $6.6M | Jun 2015 | |
| NNew Frontier Corporation | Unknown | $478M | — |
| Series C | $50M | — |
Top Co-Investors
Last updated: 27 September 2026